Effectiveness of voriconazole in the treatment of Aspergillus fumigatus–associated asthma (EVITA3 study) Joshua Agbetile, MD, Michelle Bourne, RGN, Abbie.

Slides:

Advertisements

Similar presentations

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,

Advertisements

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Incidence of parentally reported and clinically diagnosed food hypersensitivity in the first year of life Carina Venter, BSc, Brett Pereira, MRCP, Jane.

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Alveolar nitric oxide and asthma control in mild untreated asthma

The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy Jennifer M. Maloney, MD, Magnus Rudengren, BSc, Staffan.

Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery Albertien A.C. Aukema,

Risk of an asthma exacerbation after bariatric surgery in adults

Pharmacologic rationale for treating allergic and nonallergic rhinitis

Differential effects of maintenance long-acting β-agonist and inhaled corticosteroid on asthma control and asthma exacerbations Peter G. Gibson, MBBS(Hons),

Incidence of parentally reported and clinically diagnosed food hypersensitivity in the first year of life Carina Venter, BSc, Brett Pereira, MRCP, Jane.

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults Peter S. Creticos, MD, Jennifer Maloney,

Epidemic asthma and the role of the fungal mold Alternaria alternata

Severe winter asthma exacerbations can be prevented by omalizumab, but there is no carryover effect Peter D. Sly, MD, DSc, Julie Varghese, BHMS, PGDCTM,

Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study John M. Brehm, MD, MPH, Brooke Schuemann, BS,

Is 9 more than 2 also in allergic airway inflammation?

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Lung function decline and variable airway inflammatory pattern: Longitudinal analysis of severe asthma Christopher Newby, PhD, Joshua Agbetile, MRCP,

Steven W. Yancey, MSc, Hector G. Ortega, MD, Oliver N

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

A randomized multicenter study evaluating Xolair persistence of response after long- term therapy Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma,

Allergy testing in predicting outcome of open food challenge to peanut

Treatment of chronic autoimmune urticaria with omalizumab

A network-based analysis of the late-phase reaction of the skin

Nonadherence to Asthma Treatment: Getting Unstuck

Peter M. Wolfgram, MD, David B. Allen, MD

Etiology of asthma exacerbations

William J. Calhoun, MD, Tmirah Haselkorn, PhD, Dave P

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

Reply Journal of Allergy and Clinical Immunology

Donald W. MacGlashan, MD, PhD, Sarbjit S. Saini, MD

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12- month follow-up analysis Pranabashis Haldar, MD, Christopher E. Brightling,

Debra J. Palmer, PhD, Thomas R. Sullivan, BMa&CompSc(Hons), Michael S

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

What are the best outcome measurements for atopic eczema

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

What is an “eosinophilic phenotype” of asthma?

Medication use in children with asthma in Finland from 1995 to 2006

Autophagy: Nobel Prize 2016 and allergy and asthma research

Vascular remodeling is a feature of asthma and nonasthmatic eosinophilic bronchitis Salman Siddiqui, MRCP, Amanda Sutcliffe, BSc (Hons), Aarti Shikotra,

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

House dust mite sublingual immunotherapy: Results of a US trial

Mary F. Linehan, PhD, Timothy L. Frank, MD, Michelle L

Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: A randomized, double-blind, placebo-controlled study Giovanni B. Pajno,

Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down Eric D. Bateman, MD, Loretta Jacques, PhD,

Prevention of food allergy: Beyond peanut

Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet Stephen.

The Editors' Choice Journal of Allergy and Clinical Immunology

Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis Philippe-Jean Bousquet, MD, Christophe Combescure, PhD,

Short course of systemic corticosteroids in sinonasal polyposis: A double-blind, randomized, placebo-controlled trial with evaluation of outcome measures

The Editors' Choice Journal of Allergy and Clinical Immunology

Bronchoalveolar lavage invariant natural killer T cells are not increased in asthma Kugathasan Mutalithas, MRCP, Joanne Croudace, PhD, Cristina Guillen,

Macrolide antibiotics and asthma treatment

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Asthma: The past, future, environment, and costs

Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization.

Environmental factors and eosinophilic esophagitis

Sublingual immunotherapy for peanut allergy: Clinical and immunologic evidence of desensitization Edwin H. Kim, MD, J. Andrew Bird, MD, Michael Kulis,

The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy Jennifer M. Maloney, MD, Magnus Rudengren, BSc, Staffan.

Safety and efficacy of repeated monthly carboplatin desensitization

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

The influence of asthma control on the severity of virus-induced asthma exacerbations David J. Jackson, MRCP, PhD, Maria-Belen Trujillo-Torralbo, BSc,

Primary prevention of asthma and allergy

Modeling asthma exacerbations through lung function in children

Presentation transcript:

Effectiveness of voriconazole in the treatment of Aspergillus fumigatus–associated asthma (EVITA3 study) Joshua Agbetile, MD, Michelle Bourne, RGN, Abbie Fairs, PhD, Beverley Hargadon, RGN, Dhananjay Desai, MD, Clare Broad, Joseph Morley, BSc, Peter Bradding, DM, FRCP, Christopher E. Brightling, PhD, FRCP, Ruth H. Green, DM, FRCP, Pranabashis Haldar, DM, MRCP, Catherine H. Pashley, PhD, Ian D. Pavord, DM, FRCP, Andrew J. Wardlaw, PhD, FRCP Journal of Allergy and Clinical Immunology Volume 134, Issue 1, Pages 33-39 (July 2014) DOI: 10.1016/j.jaci.2013.09.050 Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Recruitment of subjects. Of the 184 patients with asthma and IgE sensitization approached to take part in the study, approximately half declined to be involved. A minority did not meet the inclusion criteria, mainly because they had less than 2 exacerbations in the previous 12 months. Of the 65 subjects randomized to drug or placebo, 6 (5 in the placebo group) changed their minds between visits 1 and 2. Of those who took the treatment and were included in the analysis, 1 subject in the placebo group was lost to follow-up between visits 2 and 3, and 2 subjects in the placebo group and 3 in the voriconazole group did not complete the full course of treatment (although 2 of these took >2 months of drug). Journal of Allergy and Clinical Immunology 2014 134, 33-39DOI: (10.1016/j.jaci.2013.09.050) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Severe exacerbations. There was a linear increase in the number of severe exacerbations in both groups with no treatment effect. The total number of exacerbations in the placebo group was 38, with 37 in the voriconazole group, which represented a 54% reduction from baseline in both groups. Five patients in the voriconazole group and 9 subjects in the placebo group did not have exacerbations. This difference was not significant. Journal of Allergy and Clinical Immunology 2014 134, 33-39DOI: (10.1016/j.jaci.2013.09.050) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Patient-reported outcomes. There was a significant improvement in quality-of-life scores in both groups from baseline during the course of treatment, with the voriconazole group increasing from a mean of 4.55 to a maximum of 5.3 and the placebo group increasing from a mean of 4.66 to a maximum of 5.6 (P < .001). There was no significant difference between groups, and the improvement was not maintained after the treatment period had finished. A similar pattern was observed for both the asthma control score and the mean VAS score, with a significant improvement from baseline in both groups during the treatment period but no significant difference between groups and a return toward baseline value immediately on stopping treatment. Journal of Allergy and Clinical Immunology 2014 134, 33-39DOI: (10.1016/j.jaci.2013.09.050) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E1 Journal of Allergy and Clinical Immunology 2014 134, 33-39DOI: (10.1016/j.jaci.2013.09.050) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E2 Journal of Allergy and Clinical Immunology 2014 134, 33-39DOI: (10.1016/j.jaci.2013.09.050) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E3 Journal of Allergy and Clinical Immunology 2014 134, 33-39DOI: (10.1016/j.jaci.2013.09.050) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions